According to a study published in ‘Diabetes Technology and Therapeutics’, the advanced hybrid closed-loop (AHCL) system, MiniMed 780G™ was found to be safe and improves glycemic outcome in 2- to 6-year-old children with type 1 diabetes and the diabetes distress of caregivers.

      This was an open-label prospective study (n = 35) with historical controls matched by treatment unit, diabetes duration, age, gender, and baseline treatment modality. The inclusion criteria were type 1 diabetes diagnosis >6 months, total daily dose of insulin ≥8 U/day, HbA1c <10% , and capability to use insulin pump and continuous glucose monitoring. The MiniMed 780G™ AHCL in SmartGuard™ Mode was used for 12 weeks. Parental diabetes distress was evaluated with a validated problem areas in diabetes—parent, revised (PAID-PR) survey.

No events of diabetic ketoacidosis or severe hypoglycemia occurred during the study period. Between 0 and 12 weeks, there is observed significant improvements in the HbA1c, mean sensor glucose value (SG). Time above range (TAR) got decreased and Time in range (TIR) got increased significantly. No significant change was observed in time below range (TBR). PAID- PR score decreased from 37.5 (18.2) to 27.5 (14.8) (P = 0.006).

MiniMed 780G™ AHCL is a safe system and 12-week use revealed considerable improvements in glycemic control in 2- to 6-year-old children with type 1 diabetes. A reduction in parental diabetes distress was also observed during the study period.